BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
ARWR upcoming catalysts
Arrowhead Pharmaceuticals: 1 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (0 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 3 readout(s) and 0 FDA event(s). Subscribe to ARWR (.ics).
Drugs: Plozasiran, ARO-ALK7
Upcoming FDA decision events
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| No upcoming PDUFA date or AdCom found. | |||||
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2027-02 est. | P1/P2 | Arrowhead Pharmaceuticals ARWR | NCT06937203 A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus | Obesity; Diabetes Mellitus, Type 2 | recruiting | 150 |
FDA decision events, last 12 months
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| No FDA decision events in this window. | |||||
Trial readouts, last 12 months
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-06-17 | P3 | Arrowhead Pharmaceuticals ARWR | NCT06347016 Study of Plozasiran in Adults With Severe Hypertriglyceridemia | Severe Hypertriglyceridemia | completed | 311 |
| 2026-06-12 | P3 | Arrowhead Pharmaceuticals ARWR | NCT06347003 Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia | Severe Hypertriglyceridemia | completed | 446 |
| 2026-06-01 | P3 | Arrowhead Pharmaceuticals ARWR | NCT06347133 Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia | Hypertriglyceridemia | completed | 1456 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.